Pharmion Preps For MDS Competition; Vidaza Dosing Under Study
Pharmion is testing more convenient dosing schedules for its myelodysplastic syndromes drug Vidaza (azacitidine) ahead of potential market entry of competitors in the fall
You may also be interested in...
MGI Pharma is evaluating more convenient dosing strategies for its oncologic Dacogen in patients with myelodysplastic syndromes
Pharmion will use proceeds from its initial public offering to file an accelerated approval NDA for its bone marrow disorder agent Vidaza (azacitidine) and begin a confirmatory Phase IV clinical trial
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011